|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
���� |
|
HIV |
|
AIDS |
| ��������������� | |
|
���¸� |
|
��� |
| PubMed | |
|
Article by |
|
Article by |
HIV-1������HIV/AIDS
���¸�, ���
�㽭��ѧҽѧԺ������һҽԺƤ����, ���� 310003
����HIV/AIDS���м��ӻ����鷢չ��ϣ������Ӧ����Ч��ȫ���۵�����.������HIV-1����Ļ����о�����������ȡ���˺ܴ�ķ�չ,������Ҫ����HIV-1�����յ��IJ�������������Ӧ����ٴ�����Ľ�չ.
[2] Mascola JR,Lewis MG,Stiegler G,et al.Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.J Virol,1999,73(5):4009-4018.
[3] Baba TW,Liska V,Hofmann-Lehmann R,et al.Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.Nat Med,2000,6(2):200-206.
[4] Haigwood NL,Watson A,Sutton WF,et al.Passive immune globulin therapy in the SIV/macaque model:early intervention can alter disease profile.Immunol Lett,1996,51(1-2):107-114.
[5] Parren PW,Marx PA,Hessell AJ,et al.Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.J Virol,2001,75(17);8340-8347.
[6] Belshe RB,Stevens C,Gorse GJ,et al.Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gpl20:a phase 2 study in higher-and lower-risk volunteers.J Infect Dis,2001,183(9);1343-1352.
[7] Chow YH,Chiang BL,Lee YL,et al.Development of Thl and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.J Immunol,1998,160(3):1320-1329.
[8] Barouch DH,Santra S,Tenner-Racz K,et al.Potent CD4 + T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.J Immunol,2002,168(2);562-568.
[9] Belyakov IM,Ahlers JD,Clements JD,et al.Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.J Immunol,2000,165(11);6454-6462.
[10] Moore AC,Kong WP,Chakrabarti BK,et al.Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.J Virol,2002,76(1);243-250.
[11] Barouch DH,Santra S,Schmitz JE,et al.Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.Science,2000,290(5491);486-492.
[12] Amara RR,Villinger F,Altman JD,et al.Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.Science,2001,292(5514);69-74.
[13] Calarota SA,Kjerrstrom A,Islam KB,et al.Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.Hum Gene Ther,2001,12(13):1623-1637.
[14] Pialoux G,Gahery-Segard H,Sermet S,et al.Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers.AIDS,2001,15(10);1239-1249.
[15] Kaslow RA,Rivers C,Tang J,et al.Polymorphisms in HLA class �� genes associated with both favorable prognosis of human immunodeficiency virus(HIV)type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.J Virol,2001,75(18);8681-8689.
[16] Hel Z,Tsal WP,Thornton A,et al.Potentiation of simian immunodeficiency virus(SIV)-specific CD4(+)and CDS(+)T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.J Immunol,2001,167(12);7180-7191.
[17] Zhong W,Roberts AD,Woodland DL.Antibody-independent antiviral function of memory CD4 + T cells in vivo requires regulatory signals from CD8 + effector T cells.J Immunol,2001,167(3):1379-1386.
[18] Norris PJ,Rosenberg ES.Cellular immune response to human immunodeficiency virus.AIDS,2001,15(Suppl 2):S16-S21.
[19] Toledo H,Baly A,Castro O,et al.A phase I clinical trial of a multiepitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.Vaccine,2001,19(30):4328-4336.
[20] Lambert JS,Keefer M,Mulligan M J,et al.A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.Vaccine,2001,19(23-24);3033-3042.
[21] Birx DL,Loomis-Price LD,Aronson N,et al.Efficacy testing of recombinant human immunodeficiency virus(HIV)gpl60 as a therapeutic vaccine in early-stage HIV-1-infected volunteers.rgpl60 Phase �� Vaccine Investigators.J Infect Dis,2000,181(3);881-889.
[22] Mulligan M J,Weber J.Human trials of HIV-1 vaccines.AIDS,1999,13(Suppl A):S105-S112.
[23] Ruxiungtham K,Phanuphak P.Update on HIV/AIDS in Thailand.J Med Assoc Thai,2001,84(Suppl 1);S1-S17.
[24] Cohen J.AIDS vaccines show promise after years of frustration.Science,2001,291(5509):1686-1688.